Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: SJM stock price vs EW: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at EW's multiple
Needs EW P/S.
Implied fair value · at SJM's multiple
Needs SJM P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
The J. M. Smucker Company · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Edwards Lifesciences Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
COCA COLA CO
SJM vs KO
PEPSICO INC
SJM vs PEP
GENERAL MILLS INC
SJM vs GIS
COLGATE PALMOLIVE CO
SJM vs CL
Lamb Weston Holdings, Inc.
SJM vs LW
HORMEL FOODS CORP /DE/
SJM vs HRL
ABBOTT LABORATORIES
SJM vs ABT
JOHNSON & JOHNSON
SJM vs JNJ
Medtronic plc
SJM vs MDT
BOSTON SCIENTIFIC CORP
SJM vs BSX
BAXTER INTERNATIONAL INC
SJM vs BAX
DENTSPLY SIRONA Inc.
SJM vs XRAY
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe SJM can materially improve margins and de-lever its balance sheet toward EW-like quality, then consider the stock for relative re-rating potential because the current valuation gap is large; otherwise, the weak profitability, low ROIC, and elevated leverage argue for caution.
On a P/S basis, SJM trades at 1.4x versus EW at 8.1x, and the provided EW-implied valuation framework suggests a much higher implied price than SJM's current $116.49. However, that gap is driven by EW's substantially superior profitability and growth profile, not a like-for-like mispricing.
Supporting Metrics
